Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo

20 May 2023

Abstract excerpt

BACKGROUND: Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a multifunctional chaperone/scaffold protein that is upregulated in various cancers and plays a pro-cancer role. FL3 is a synthetic flavagline drug that inhibits cancer cell proliferation by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clusterin in disease pathology
Share to Heat shock proteins research
Share to Prostate Cancer Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37210546
DOI: 10.1186/s13046-023-02695-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoPMID 37210546Read ↗

Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivoSemantic proximity Read ↗

Identification of key molecules for castration resistance prostate cancer by bioinformatic analysisSemantic proximity Read ↗

LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.Semantic proximity Read ↗

CDK6 is upregulated and may be a potential therapeutic target in enzalutamide-resistant castration- resistant prostate cancer by bioinformatic analysisSemantic proximity Read ↗

Investigation of the Effects of Galectin-1 on Enzalutamide Sensitivity and Cellular Functions in Prostate Cancer Cells and Its Clinical Diagnostic ValueSemantic proximity Read ↗

Integrated Bioinformatics Analysis Identified ASNS and DDIT3 as the Therapeutic Target in Castrate-Resistant Prostate CancerSemantic proximity Read ↗

Exploration of the influence of GOLGA8B on prostate cancer progression and resistance of castration-resistant prostate cancer to cabazitaxelSemantic proximity Read ↗

Identification of Hub Gene and Potential Drugs for Enzalutamide Resistant Castration-Resistant Prostate Cancer Depend On Bioinformatics AnalysisSemantic proximity Read ↗

Bioinformatics and system biology approaches for identifying potential therapeutic targets for prostate cancerSemantic proximity Read ↗

Exploiting epigenetic targets to overcome taxane resistance in prostate cancerSemantic proximity Read ↗

Exploiting Epigenetic Targets to Overcome Taxane Resistance in Prostate CancerSemantic proximity Read ↗

An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.